Cardiac Biomarkers Market to Reach USD 20.7 Billion by 2030

According to the latest market research study published by P&S Intelligence, the cardiac biomarkers market is anticipated to reach a value of USD 20,718.8 million by 2030, advancing at a compound annual growth rate (CAGR) of 10.5%. This surge is driven by the rising incidence of acute coronary syndrome (ACS), advancements in cardiac biomarker technology, growing demand for point-of-care (POC) testing kits, and the need for high specificity in detecting cardiac disorders, especially myocardial infarction.

Troponin, which accounted for over 35% of revenue in recent years, will continue to expand at a substantial rate throughout this decade. Its exceptional specificity and ability to detect cardiac issues, such as ACS, make it a key tool in diagnosing these conditions.

Moreover, the prevalence of myocardial infarction will further fuel the market, as troponin is the primary biomarker used for detecting this condition. The myocardial muscle creatine kinase segment is also expected to see significant growth in the coming years, following troponin.

Laboratory testing dominated the market with a 60% revenue share and is projected to maintain its leading position. This dominance is attributed to rising healthcare expenditure, improvements in healthcare infrastructure, increasing disposable income, and initiatives from both public and private sectors aimed at preventing heart diseases.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cardiac-biomarker-market

Point-of-care testing is expected to grow at a faster pace in the coming years, as healthcare providers increasingly adopt this method to monitor patients with chest pain in critical care settings.

In 2021, myocardial infarction was the leading contributor to the market, generating approximately USD 3 billion in revenue. This trend is expected to continue throughout the decade, driven by the rising incidence of myocardial infarction due to poor dietary habits, sedentary lifestyles, smoking, and coronary artery disease.

The increasing demand for biomarker tests for early detection of heart failure is another key factor contributing to the growth of the cardiac biomarkers market.

North America held the largest market share, over 35%, in 2021, driven by the growing use of biomarkers in precision medicine, strategic initiatives by market players, and increasing adoption of biomarkers for detecting cardiac diseases. The U.S. was a major contributor to this dominance due to its significant base of market players and high R&D investments in healthcare.

The number of individuals affected by acute coronary syndrome continues to rise, ensuring sustained demand for cardiac biomarkers in the future.

About P&S Intelligence

 

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

 

Contact:
Chandra Mohan
AVP – Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com